Cargando…

Magnetic resonance image-based tomotherapy planning for prostate cancer

PURPOSE: To evaluate and compare the feasibilities of magnetic resonance (MR) image-based planning using synthetic computed tomography (sCT) versus CT (pCT)-based planning in helical tomotherapy for prostate cancer. MATERIALS AND METHODS: A retrospective evaluation was performed in 16 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Sang Hoon, Kim, Jinsung, Chung, Yoonsun, Keserci, Bilgin, Pyo, Hongryull, Park, Hee Chul, Park, Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Radiation Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113151/
https://www.ncbi.nlm.nih.gov/pubmed/32229809
http://dx.doi.org/10.3857/roj.2020.00101
Descripción
Sumario:PURPOSE: To evaluate and compare the feasibilities of magnetic resonance (MR) image-based planning using synthetic computed tomography (sCT) versus CT (pCT)-based planning in helical tomotherapy for prostate cancer. MATERIALS AND METHODS: A retrospective evaluation was performed in 16 patients with prostate cancer who had been treated with helical tomotherapy. MR images were acquired using a dedicated therapy sequence; sCT images were generated using magnetic resonance for calculating attenuation (MRCAT). The three-dimensional dose distribution according to sCT was recalculated using a previously optimized plan and was compared with the doses calculated using pCT. RESULTS: The mean planning target volume doses calculated by sCT and pCT differed by 0.65% ± 1.11% (p = 0.03). Three-dimensional gamma analysis at a 2%/2 mm dose difference/distance to agreement yielded a pass rate of 0.976 (range, 0.658 to 0.986). CONCLUSION: The dose distribution results obtained using tomotherapy from MR-only simulations were in good agreement with the dose distribution results from simulation CT, with mean dose differences of less than 1% for target volume and normal organs in patients with prostate cancer.